STAT3 and myocardial infarction: Rosuvastatin administered on the day before in vivo myocardial infarction (8 mg/kg single dose), and thereafter at 4 mg/kg orally for five weeks, enhanced p-STAT3/t-STAT3 in the peri-infarct area [126].